Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Convene, 133 Houndsditch, London, EC3A 7DB

  1. Events
  2. Venues
  3. Convene, 133 Houndsditch, London, EC3A 7DB
Events at this venue
Today

BioTrinity 2025

BioTrinity 2025 will be OBN's flagship two-day conference, taking place in its 19th year. The event will feature presentations from R&D companies at Series A [...]

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2024 | Hlx Life Sciences

Site by theLEAP

Go to Top